EXEL vs REGN · P/E 17, rev $1.24B vs P/E 14, rev $4.29B
Exelixis Inc (EXEL) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EXEL revenue for 2026-07-03 was $1.24B. Net income was $422.5M. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EXEL and REGN stock pages for the full models.
Not investment advice.